Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort
DOI:
https://doi.org/10.20344/amp.5032Abstract
Introduction: Natalizumab is licensed as monotherapy for relapsing–remitting multiple sclerosis. Since pivotal studies showing natalizumab efficacy, several subsequent studies confirmed the reduction in annualized relapse rate and the slowing of disability progression. Nevertheless, ‘real-world’ data, namely in Portugal, are still scarce. We intend to report demographic and clinical data of the cohort of patients treated with natalizumab in the multiple sclerosis Clinic of Centro Hospitalar São João, based on daily practice.
Material and Methods: We have conducted a retrospective study of multiple sclerosis patients who had been treated with natalizumab (at least one dose) from January 2007 to May 2013 in our Center. We have gathered information about demography, baseline disease, natalizumab treatment, and outcome.
Results: We have found 66 patients treated with natalizumab since 2007 in our center. The majority (65.2%) were female, with a mean age of 35 years, and mean disease duration of 9.5 years. Almost all patients (93.9%) had received a prior multiple sclerosis immunomodulatory therapy. Patients have been treated with natalizumab on an average time of 24 months, with a statistically significant reduction in Annualized Relapse Ratio (- 1.9, p < 0.001) and Expanded Disability Status Scale score (- 0.8, p < 0.001). One patient has developed progressive multifocal leukoencephalopathy; other adverse effects have been uncommon.
Discussion: In general, our results fit those earlier reported in other post-marketing studies. Lack of MRI data and retrospective design are the most important limitations of our study.
Conclusion: Our study confirms natalizumab efficacy and safety in the treatment of relapsing-remitting multiple sclerosis in a ‘realworld’ practice.
Keywords: Multiple Sclerosis; Natalizumab; Treatment Outcome; Antibodies, Monoclonal, Humanized/ adverse effects; Leukoencephalopathy, Progressive Multifocal/chemically induced.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.